A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical TrialSai‐Hong Ignatius Ou, Trever G. Bivona, Jorge H. Limón-Pacheco et al.|Journal of Thoracic Oncology|2020Cited by 74
Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signalingJohanna C. Bendell, S.‐H.I. Ou, Susanna V. Ulahannan et al.|European Journal of Cancer|2020Cited by 27